시장보고서

상품코드

1574965

프라이온병 치료 시장 : 유형별, 치료별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Prion Disease Treatment Market, By Type, By Treatment, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사: 구분자

AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 3,250

￦ 4,672,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,650

￦ 6,685,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650

￦ 8,123,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

프라이온병 치료 시장 규모는 2023년 49억 8,498만 달러로 2024년부터 2032년까지 4.99%의 CAGR로 확대될 것으로 예상됩니다.

프라이온병 치료 시장 - 시장 역학

특정 프라이온 균주에 대한 맞춤형 의료에 대한 관심 증가로 틈새 시장 성장 촉진

특정 프라이온 균주에 대한 맞춤 의료에 대한 관심이 높아진 것이 시장 확대의 주요 요인입니다. 이 접근법은 진단과 치료를 각기 다른 프라이온 균주 집단의 고유한 특성에 맞게 조정하여 개입의 효과를 높이는 것입니다. 미국 국립신경질환 및 뇌졸중 연구소(NINDS)의 최근 데이터에 따르면, 맞춤형 의료 전략은 프라이온병의 진단 정확도를 최대 30%까지 향상시킬 수 있는 것으로 나타났습니다. 이러한 발전은 보다 정확하고 효과적인 치료 옵션의 가능성을 부각시켜 시장 역학에 직접적인 영향을 미칠 수 있습니다.

헬스케어 분야가 개인화된 접근 방식을 점점 더 많이 수용함에 따라 특수 진단 도구와 맞춤형 치료법에 대한 수요가 증가하고 있습니다. 이러한 수요는 파킨슨병 관리의 틈새 시장에서 혁신과 성장을 촉진하고, 복잡한 신경 퇴행성 질환을 다루는 데 있어 개인화된 의료의 혁신 가능성을 강조하고 있습니다.

프라이온병 치료 시장 - 주요 인사이트

당사의 리서치 애널리스트가 공유한 분석에 따르면, 세계 시장은 예측 기간(2024-2032) 동안 연평균 약 4.99%의 CAGR로 매년 성장할 것으로 추정됩니다.

유형별로는 크로이츠펠트 야콥병(CJD)이 2023년 가장 큰 시장 점유율을 차지할 것으로 예측되었습니다.

치료별로는 2023년 항우울제가 주요 유형으로 꼽혔습니다.

지역별로는 북미가 2023년 주요 수익원이었습니다.

프라이온병 치료 시장 - 세분화 분석:

세계 프라이온병 치료 시장은 유형, 치료, 최종사용자 및 지역을 기준으로 세분화됩니다.

시장은 크로이츠펠트 야콥병(CJD), 변종 크로이츠펠트 야콥병(CJD), 변종 프로테아제 감수성 프라이온병, 게르스트만-스트로이슬러-샤인커병, 기타 등 4가지 유형으로 분류됩니다. 프라이온병 치료제 시장에서 가장 두드러지고 중요한 부문은 크로이츠펠트 야콥병(CJD)으로, CJD는 인간에게 가장 흔한 프라이온병으로 다른 프라이온병에 비해 유병률이 높기 때문에 주요 초점이 되고 있습니다. 크로이츠펠트 야콥병에는 산발성, 유전성, 후천성 등 여러 가지 형태가 있습니다. CJD의 치료 상황은 연구에 대한 높은 관심과 중증도 때문에 특히 활발하며, CJD에 대한 효과적인 치료법과 치료법 개발 노력이 시장을 주도하는 경우가 많으며, CJD 시장은 CJD 시장을 지배하는 부문입니다.

CJD 시장은 치료법별로 항우울제, 항정신병약, 기타의 두 가지 범주로 나뉩니다. 프라이온병 치료 시장에서 항우울제는 항정신병약에 비해 항우울제가 더 두드러지고 중요합니다. 항우울제는 프라이온병, 특히 크로이츠펠트 야콥병(CJD)과 같은 프라이온병 환자에서 흔히 나타나는 우울증, 불안, 흥분과 같은 증상을 완화하는 데 자주 사용됩니다. 프라이온병에 대한 치료법은 없지만, 항우울제는 이차적인 증상을 관리하여 삶의 질을 개선하는 데 도움이 됩니다. 항우울제는 프라이온병 연구 및 치료 전략에서 항우울제의 중요성이 강조됨에 따라 이 분야는 시장에서 더욱 중요하고 우월한 위치를 차지하고 있습니다.

프라이온병 치료 시장 - 지리적 인사이트

북미에서 프라이온병 치료는 현재 진행 중인 연구 분야이며, 임상적 선택은 제한적입니다. 크로이츠펠트 야콥병(CJD)과 같은 프라이온병은 드물고 진행성 신경 퇴행을 특징으로 합니다. 치료 전략은 주로 대증요법과 실험적 치료가 중심입니다. 효과적인 치료제를 개발하기 위한 연구가 중요시되고 있으며, 유전자 치료, 면역 치료와 같은 새로운 화합물 및 접근법을 모색하기 위한 여러 임상시험이 진행되고 있습니다.

북미 규제 환경은 자금 지원과 규제 경로를 통해 이러한 노력을 지원하고 있지만, 프라이온병의 복잡성 때문에 어려움이 있습니다. 연구 기관, 의료 서비스 제공자 및 제약 회사 간의 협력은 치료 옵션을 발전시키고 환자 결과를 개선하는 데 매우 중요합니다.

프라이온병 치료 시장 - 경쟁 상황:

프라이온병 치료의 경쟁 구도에는 프라이온병에 특화된 다양한 생명공학 및 제약회사들이 이 질병에 특화된 과제를 해결하기 위해 노력하고 있으며, CureVac AG는 mRNA 기술을 잠재적인 치료법으로 모색하고 있고, Prionics AG는 프라이온병 진단을 전문으로 하고 있습니다. 뉴로텍 파마슈티컬스(Neurotech Pharmaceuticals)와 프로테나 바이오사이언스(Protona Biosciences)는 프라이온병과 관련된 신경 퇴행성 질환 치료제를 개발하고 있으며, 알닐람 파마슈티컬스(Alnylam Pharmaceuticals)와 이오니스 파마슈티컬스(IONIS Pharmaceuticals)는 프라이온병 치료에 영향을 미칠 수 있는 RNA 기반 치료제를 개발하고 있습니다. 영향을 미칠 수 있는 RNA 기반 치료제를 개발하고 있습니다. 바이오젠, 일라이 릴리, 암젠과 같은 주요 기업들은 프라이온병 치료로 이어질 수 있는 다양한 신경 퇴행성 연구에 투자하고 있습니다. 제네텍(로슈 그룹)은 혁신적인 신경학 치료에 집중하고 있으며, 웨이브 라이프 사이언스(Wave Life Sciences)와 오르파자임 A/S는 각각 RNA 표적치료제와 희귀질환 치료제를 연구하고 있습니다. 세이지 테라퓨틱스(Sage Therapeutics)는 신경 퇴행성 질환을, 엑렉터(Alector)는 면역 치료제를 개발하고 있으며, 테트라 디스커버리 파트너스(Tetra Discovery Partners)는 프라이온병과 교차할 수 있는 신경 질환 치료법을 연구하고 있습니다. 이 다양한 기업들은 프라이온병의 복잡한 특성을 해결하기 위해 현재 진행 중인 노력과 혁신을 강조하고 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제11장 주요 벤더 분석 - 프라이온병 치료 업계

경쟁 대시보드
기업 개요
- CureVac AG
- Prionics AG
- Neurotech Pharmaceuticals
- Prothena Biosciences
- Alnylam Pharmaceuticals
- IONIS Pharmaceuticals
- Biogen
- Eli Lilly and Company
- Amgen Inc.
- Genentech
- Wave Life Sciences
- Orphazyme A/S
- Sage Therapeutics
- Alector Inc.
- Tetra Discovery Partners

제12장 애널리스트의 전방위 전망

ksm 24.11.05

REPORT HIGHLIGHT

Prion Disease Treatment Market size was valued at USD 4,984.98 million in 2023, expanding at a CAGR of 4.99% from 2024 to 2032.

Prion diseases are a group of progressive neurodegenerative disorders caused by abnormal, misfolded proteins known as prions. These prions induce other proteins in the brain to also misfold, leading to brain damage and severe neurological symptoms. The most well-known prion diseases include Creutzfeldt-Jakob disease, Bovine Spongiform Encephalopathy (mad cow disease), and Kuru. Symptoms often involve rapid cognitive decline, motor dysfunction, and behavioral changes. Currently, there is no cure for prion diseases, and treatment mainly focuses on alleviating symptoms and providing supportive care. Research is ongoing to find effective therapies, but the unique nature of prions and their ability to resist conventional treatments pose significant challenges. Early diagnosis and management can help in improving the quality of life for affected individuals.

Prion Disease Treatment Market- Market Dynamics

Rising interest in personalized medicine for specific prion strains drives niche market growth.

The growing interest in personalized medicine for specific prion strains is a key driver of market expansion. This approach tailors' diagnostics and treatments to the unique characteristics of different population strains, enhancing the effectiveness of interventions. Recent data from the National Institute of Neurological Disorders and Stroke (NINDS) showed that personalized medicine strategies could improve diagnostic accuracy for prion diseases by up to 30%. These advancements highlight the potential for more precise and effective treatment options, directly influencing market dynamics.

As the healthcare sector increasingly embraces individualized approaches, there is a rising demand for specialized diagnostic tools and customized therapies. This demand fosters innovation and growth in the niche market for Parkinson's disease management, emphasizing the transformative potential of personalized medicine in addressing complex neurodegenerative conditions.

Prion Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.99% over the forecast period (2024-2032)

Based on Type segmentation, Creutzfeldt-Jakob Disease (CJD) was predicted to show maximum market share in the year 2023

Based on Treatment segmentation, antidepressant medications was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Prion Disease Treatment Market- Segmentation Analysis:

The Global Prion Disease Treatment Market is segmented on the basis of Type, Treatment, End User, and Region.

The market is divided into four categories based on Type: Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (CJD), Variably Protease-Sensitive Prionopathy, Gerstmann-Straussler-Scheinker Disease, Others. In the prion disease treatment market, Creutzfeldt-Jakob Disease (CJD) is the most prominent and significant segment. CJD is the most common prion disease in humans, and it is a major focus due to its prevalence compared to other prion disorders. Creutzfeldt-Jakob Disease comes in several forms, including sporadic, genetic, and acquired. The sporadic form is the most common and occurs without any known cause. The treatment landscape for CJD is particularly active due to the high level of research interest and the severe nature of the disease. Efforts to develop effective treatments or therapies for CJD often drive the market, making it the dominant segment.

The market is divided into two categories based on Treatment: Antidepressants, Antipsychotic agents, and Others. In the prion disease treatment market, antidepressant medications are more prominent and significant compared to antipsychotic agents. Antidepressants are often used in the management of prion diseases, particularly for alleviating symptoms such as depression, anxiety, and agitation, which are common in patients with prion disorders like Creutzfeldt-Jakob Disease (CJD). Although there is no cure for prion disease, antidepressants can help improve the quality of life by managing secondary symptoms. The focus on antidepressants in research and treatment strategies for prion diseases makes this segment more significant and dominant in the market.

Prion Disease Treatment Market- Geographical Insights

In North America, prion disease treatment is an area of ongoing research with limited clinical options. Prion diseases, such as Creutzfeldt-Jakob Disease (CJD), are rare and characterized by progressive neurodegeneration. Treatment strategies focus on symptomatic management and experimental therapies. There is a significant emphasis on research to develop effective drugs, with several clinical trials exploring novel compounds and approaches, such as gene therapy and immunotherapy.

The North American regulatory environment supports these efforts through funding and regulatory pathways, though the complexity of prion diseases presents challenges. Collaboration among research institutions, healthcare providers, and pharmaceutical companies is crucial for advancing treatment options and improving patient outcomes.

Prion Disease Treatment Market- Competitive Landscape:

The competitive landscape for prion disease treatment includes a variety of biotech and pharmaceutical companies tackling the unique challenges of these disorders. CureVac AG is exploring mRNA technologies for potential treatments, while Prionics AG specializes in prion disease diagnostics. Neurotech Pharmaceuticals and Prothena Biosciences are developing therapies for neurodegenerative conditions that could be relevant to prion diseases. Alnylam Pharmaceuticals and IONIS Pharmaceuticals work on RNA-based therapies that may impact prion disease treatment. Major players such as Biogen, Eli Lilly and Company, and Amgen Inc. invest in broader neurodegenerative research with potential Treatments to prion diseases. Genentech (Roche Group) focuses on innovative neurological therapies. Wave Life Sciences and Orphazyme A/S are exploring RNA-targeted and rare disease therapies, respectively. Sage Therapeutics works on neurodegenerative disorders, while Alector Inc. develops immunotherapies. Tetra Discovery Partners is also researching treatments for neurological conditions that might intersect with prion diseases. This diverse group of companies highlights the ongoing efforts and innovations aimed at addressing the complex nature of prion diseases.

Recent Developments:

In June 2024, The CHARMED collaboration unveiled a promising treatment candidate for prion diseases, potentially offering new hope for these currently untreatable and fatal conditions.

In August 2023, Elite Pharmaceuticals Inc. declared that EP-1 had been given the Fast Track designation by the FDA to treat CJD. The procedure known as "Fast Track designation" intended to speed up and simplify the development of medications aimed at treating serious or life-threatening illnesses.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PRION DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

CureVac AG
Prionics AG
Neurotech Pharmaceuticals
Prothena Biosciences
Alnylam Pharmaceuticals
IONIS Pharmaceuticals
Biogen
Eli Lilly and Company
Amgen Inc.
Genentech
Wave Life Sciences
Orphazyme A/S
Sage Therapeutics
Alector Inc.
Tetra Discovery Partners

GLOBAL PRION DISEASE TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Creutzfeldt-Jakob Disease (CJD)
Variant Creutzfeldt-Jakob Disease (CJD)
Variably Protease-Sensitive Prionopathy
Gerstmann-Straussler-Scheinker Disease
Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

Antidepressant
Antipsychotic Agents
Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Homecare settings
Others

GLOBAL PRION DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Prion Disease Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Prion Disease Treatment Market Snippet by Type
- 2.1.2. Prion Disease Treatment Market Snippet by Treatment
- 2.1.3. Prion Disease Treatment Market Snippet by End User
- 2.1.4. Prion Disease Treatment Market Snippet by Country
- 2.1.5. Prion Disease Treatment Market Snippet by Region
2.2. Competitive Insights

3. Prion Disease Treatment Key Market Trends

3.1. Prion Disease Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Prion Disease Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Prion Disease Treatment Market Opportunities
3.4. Prion Disease Treatment Market Future Trends

4. Prion Disease Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Prion Disease Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Prion Disease Treatment Market Landscape

6.1. Prion Disease Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Prion Disease Treatment Market - By Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
- 7.1.2. Creutzfeldt-Jakob Disease (CJD)
- 7.1.3. Variant Creutzfeldt-Jakob Disease (CJD)
- 7.1.4. Variably Protease-Sensitive Prionopathy
- 7.1.5. Gerstmann-Straussler-Scheinker Disease
- 7.1.6. Others

8. Prion Disease Treatment Market - By Treatment

8.1. Overview
- 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
- 8.1.2. Antidepressant
- 8.1.3. Antipsychotic Agents
- 8.1.4. Others

9. Prion Disease Treatment Market - By End User

9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 9.1.2. Hospitals
- 9.1.3. Homecare settings
- 9.1.4. Others

10. Prion Disease Treatment Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Prion Disease Treatment Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Prion Disease Treatment Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Prion Disease Treatment Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Prion Disease Treatment Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Prion Disease Treatment Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Prion Disease Treatment Industry

11.1. Competitive Dashboard
11.2. Company Profiles
- 11.2.1. CureVac AG
- 11.2.2. Prionics AG
- 11.2.3. Neurotech Pharmaceuticals
- 11.2.4. Prothena Biosciences
- 11.2.5. Alnylam Pharmaceuticals
- 11.2.6. IONIS Pharmaceuticals
- 11.2.7. Biogen
- 11.2.8. Eli Lilly and Company
- 11.2.9. Amgen Inc.
- 11.2.10. Genentech
- 11.2.11. Wave Life Sciences
- 11.2.12. Orphazyme A/S
- 11.2.13. Sage Therapeutics
- 11.2.14. Alector Inc.
- 11.2.15. Tetra Discovery Partners

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us